 |
 |
 |
 |
 |
 |
Treatment Name: |
 |
Phase I/II Trial of Irinotecan plus Lenalidomide in Adult Patients with Recurrent Glioblastoma Multiforme |
 |
 |
 |
 |
 |
 |
Keywords: |
 |
Lenalidomide, thalidomide, Irinotecan |
 |
 |
 |
 |
Phase: |
 |
Phase 1/2 |
 |
 |
 |
 |
 |
 |
Treatment ID#s: |
 |
VT1863
2006-0472
|
 |
 |
 |
 |
Age Group: |
 |
Adults Only |
 |
 |
 |
 |
 |
 |
Min Karnofsky Score: |
 |
60: Requires occasional assistance but is able to care for most of own needs |
 |
 |
 |
 |
Conditions: |
 |
Newly Diagnosed: N
Recurrent: Y
Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed Phase I: WHO grade III and IV malignant gliomas
Phase II: WHO grade IV malignant glioma (GBM and gliosarcoma)
|
 |
 |
 |
 |
 |
 |
Last Updated: |
 |
05/28/2008 |
 |
 |
 |
 |
Tumor Types: |
 |
Anaplastic Astrocytoma Glioblastoma Multiforme Gliosarcoma Mixed Glioma Oligodendroglioma High Grade |
 |
 |
 |
 |
 |
 |
 |
Comments: |
 |
Lenalidomide is an analogue of thalidomide, but is several times more potent as an anti-angiogenic agent without toxicities associated with thalidomide. The goal of the Phase I study is to find the highest safe dose of Irinotecan plus Lenalidomide in patients with malignant gliomas. The Phase II study will determine the effectiveness of this combination against gliomas. |
 |
 |
 |
 |
 |
 |
Treatment Type: |
 |
Chemotherapy. |
 |
 |
 |
 |
Contact: |
 |
MD Anderson Cancer Center Jan Esenwein Program Coordinator, Brain Tumor Program Contact: Jan Esenwein or Marie Woodward 1515 Holcombe Blvd Houston, TX 77030- Phone:(713)745-2264 Fax: (713)794-4999 Click here to send an email Website: www.mdanderson.org/diseases/braincancer/ |
 |
 |